PS 0-1 & any expression of PD-L1 | ESMO
1L Non-Squamous NSCLC – Recommended to PD-L1 >= 50% (with pemetrexed-platinum-doublet) - MCBS score 4
PS 0-2 & PD-L1 ≥50% | ESMO
הירשמו לקבלת עדכונים בנושאים שעלו בכתבה
נושאים קשורים: סרטן ריאות
Tislelizumab has been included in the ESMO Living Guidelines for NSCLC
1L Squamous NSCLC: Recommended regardless of PD-L1 status (with carboplatin + paclitaxel) — MCBS score 4
